Gyre Therapeutics (GYRE) FCF Payout Ratio (2023)
Gyre Therapeutics (GYRE) reported FCF Payout Ratio of 0.27 for Q3 2023, down 84.29% on a QoQ basis from 1.7 in Q2 2023.
Gyre Therapeutics (GYRE) has 1 years of FCF Payout Ratio data on file, last reported at 0.27 in Q3 2023.
- Quarterly FCF Payout Ratio changed N/A year-over-year to 0.27 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was 0.22 (changed N/A YoY) and the FY2022 annual result came in at 7.91, changed N/A from the prior year.
- FCF Payout Ratio fell to 0.27 in Q3 2023 per GYRE's latest filing, from 1.7 in the prior quarter.
- Across five years, FCF Payout Ratio topped out at 1.7 in Q2 2023 and bottomed at 0.27 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.12 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 0.27 |
| Jun 30, 2023 | 1.70 |
| Mar 31, 2023 | 0.89 |